To improve understanding of the complex global, regional and specific country issues surrounding Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME), the International Federation on Ageing (IFA), the International Agency for the Prevention of Blindness (IAPB) and the International Diabetes Federation (IDF) have come together to undertake comprehensive, two-phase, multi-country study known as the DR Barometer Study.
The DR Barometer Study, conducted in 41 countries, shines a spotlight on the prevention, assessment and treatment of diabetic eye disease (DED), as well as the real-life experiences of people living with DED and the perspectives of the clinicians they interact with.
It is our aspiration that these findings, presented in a standalone global report, and series of country reports, will prove vital to informing improved clinical management of diabetes and screening for DED, as well as the development and implementation of national health policies to address the barriers identified.
The IFA is an international non-governmental organization (NGO) with a membership base comprising government, NGOs, industry, academia and individuals in 70 countries. IFA is a voice alongside and on behalf of older adults globally and has General Consultative Status at the United Nations and its agencies including the World Health Organization.
The IAPB was established in 1975 as a coordinating, umbrella organisation to lead international efforts in blindness prevention activities. Its first major achievement was to promote the establishment of a WHO programme for prevention of blindness, with which it has remained strongly linked, and which is now embodied in the global initiative, VISION 2020: The Right to Sight.
The IDF is an umbrella organization of over 230 national diabetes associations in 170 countries and territories. It represents the interests of the growing number of people with diabetes and those at risk of developing the disease. The Federation has been leading the global diabetes community since 1950.
Bayer is a global enterprise with a focus on the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. The Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen.